Tibet Weixinkang Medicine Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Tibet Weixinkang Medicine Co., Ltd. carries a market capitalization of 3.92B, placing it among publicly traded companies globally. Its enterprise value stands at 3.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.92B |
| Enterprise Value | 3.26B |
Share Statistics
Tibet Weixinkang Medicine Co., Ltd. currently has 435.16M shares outstanding.
| Shares Outstanding | 435.16M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Tibet Weixinkang Medicine Co., Ltd. trades at a trailing price-to-earnings ratio of 16.13. The price-to-sales ratio is 3.42, and the price-to-book ratio stands at 3.98.
| PE Ratio | 16.13 |
| PS Ratio | 3.42 |
| PB Ratio | 3.98 |
| P/TBV Ratio | 2.93 |
| P/FCF Ratio | 61.50 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Tibet Weixinkang Medicine Co., Ltd. trades at an EV/EBITDA multiple of 9.68 and an EV/FCF ratio of 46.68. The EV/Sales ratio of 2.60 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.68 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.60 |
| EV / EBITDA | 9.68 |
| EV / EBIT | 9.68 |
| EV / FCF | 46.68 |
Financial Position
Tibet Weixinkang Medicine Co., Ltd. maintains a current ratio of 3.84, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.23, indicating conservative leverage, while an interest coverage ratio of 2,119.59 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.84 |
| Quick Ratio | 2.95 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 0.01 |
| Interest Coverage | 2,119.59 |
Financial Efficiency
Tibet Weixinkang Medicine Co., Ltd. posts a return on equity of 25.86 and a return on invested capital of 20.19.
| Return on Equity (ROE) | 25.86 |
| Return on Assets (ROA) | 13.93 |
| Return on Invested Capital (ROIC) | 20.19 |
| Return on Capital Employed (ROCE) | 25.70 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 12.91 |
Taxes
Over the trailing twelve months, Tibet Weixinkang Medicine Co., Ltd. has paid 37.26M in income taxes, reflecting an effective tax rate of 12.31.
| Income Tax | 37.26M |
| Effective Tax Rate | 12.31 |
Stock Price Statistics
Tibet Weixinkang Medicine Co., Ltd.'s stock has declined approximately -29.49922% over the past 52 weeks. The 50-day moving average sits at 9.46, while the 200-day moving average is 10.70.
| Beta (5Y) | N/A |
| 52-Week Price Change | -29.49922% |
| 50-Day Moving Average | 9.46 |
| 200-Day Moving Average | 10.70 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Tibet Weixinkang Medicine Co., Ltd. generated 1.25B in revenue and converted that into 265.50M in net income, yielding earnings per share of 0.63. EBITDA reached 336.30M, while operating income came in at 336.30M.
| Revenue | 1.25B |
| Gross Profit | 723.91M |
| Operating Income | 336.30M |
| Pretax Income | 302.76M |
| Net Income | 265.50M |
| EBITDA | 336.30M |
| EBIT | 336.30M |
| Earnings Per Share (EPS) | 0.63 |
Balance Sheet
Tibet Weixinkang Medicine Co., Ltd. holds 1.03B in cash and equivalents against 3.43M in total debt, resulting in a net debt position of -240.72M. Total book value stands at 1.08B, with working capital of 991.84M providing operational flexibility.
| Cash & Cash Equivalents | 1.03B |
| Total Debt | 3.43M |
| Net Debt | -240.72M |
| Equity (Book Value) | 1.08B |
| Book Value Per Share | 2.55 |
| Working Capital | 991.84M |
Cash Flow
After subtracting -69.63M in capital expenditures, free cash flow totaled -69.63M - equivalent to -0.16 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -69.63M |
| Free Cash Flow | -69.63M |
| FCF Per Share | -0.16 |
Margins
Tibet Weixinkang Medicine Co., Ltd. operates with a gross margin of 57.77, reflecting its pricing power and cost economics. The operating margin of 26.84 and net profit margin of 21.19 provide insight into operational efficiency.
| Gross Margin | 57.77 |
| Operating Margin | 26.84 |
| Pretax Margin | 24.16 |
| Profit Margin | 21.19 |
| EBITDA Margin | 26.84 |
Dividends & Yields
The company's payout ratio of 83.59 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.53 |
| Dividend Yield | N/A |
| Payout Ratio | 83.59 |
| Shareholder Yield | 6.09 |
| FCF Yield | 1.63 |
Scores
Tibet Weixinkang Medicine Co., Ltd. posts an Altman Z-Score of 8.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.93 |